Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

 

 

 

UNITEDSTATES

SECURITIESANDEXCHANGECOMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of May, 2023.

 

Commission File Number: 000-51848

 

Avricore Health Inc.

(Exact name of registrant as specified in its charter)

 

1120-789 West Pender St, Vancouver, BC, V6C 1H2

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): NO

 

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): NO

 

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

 

 

 

 

Exhibits

 

The following exhibits are included in this form 6-K:

 

Exhibit No.		Description		Date Released
1		Certification of annual filings CEO for the year ended December 31, 2022		May 1, 2023
2		Certification of annual filings CFO for the year ended December 31, 2022		May 1, 2023
3		AB Form 13-501F1 (Class 1 and 3B Participation Fee)		May 1, 2023
4		Audited annual financial statements for the year ended December 31, 2022		May 1, 2023
5		MD&A Annual filing for the year ended December 31, 2022		May 1, 2023
7		News Release- AVRICORE GRANTS OPTIONS		May 15, 2023
8		Form of Proxy		May 25, 2023
9		Management information circular		May 25, 2023
10		Notice of meeting		May 25, 2023
11		Financial Statements request form		May 25, 2023
12		Voting instruction form		May 25, 2023
13		Certification of interim filings CEO for the period ended March 31-2023		May 31, 2023
14		Certification of interim filings CFO for the period ended March 31-2023		May 31, 2023
15		Interim financial statements/report for the period ended March 31-2023		May 31, 2023
16		MD&A interim filing for the period ended March 31-2023		May 31, 2023
99.1		News Release- AVRICORE HEALTH CORPORATE UPDATES ON AUDITED RESULTS FOR 2022		May 2, 2023

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	AVRICORE HEALTH INC.
Date: June 08, 2023	By	“Kiki Smith”
		Kiki Smith
		Chief Financial Officer

 

	Persons who are to respond to the collection of information contained
SEC1815(04-09)	in this form are not required to respond unless the form displays a currently valid OMB control number